Sugi Predict

Sugi Predict / Compounds / SCHEMBL2307447

SCHEMBL2307447

SCHEMBL2307447

CC(C)n1nccc1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.44
▸ AURKA O14965 1/20 0.39
▸ CDK1 P06493 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ RET P07949 4/20 0.38
▸ CCNC P24863 2/20 0.37
▸ CDK8 P49336 2/20 0.37
▸ HASPIN Q8TF76 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CCNT1 O60563 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ CCNA1 P78396 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28154460 0.87 ALDH1A1 (0.43) NR3C2ALDH1A1AURKACDK1AURKB
SCHEMBL25660344 0.83 TGFBR1 (0.39) NR3C2ALDH1A1CDK1RETCCNC
SCHEMBL262347 0.82 ALDH1A1 (0.50) NR3C2ALDH1A1CCNCCDK8HASPIN
SCHEMBL25530100 0.82 ALDH1A1 (0.46) NR3C2ALDH1A1CDK1L3MBTL1CCNT1
SCHEMBL30420072 0.82 ALDH1A1 (0.40) NR3C2ALDH1A1CCNCCDK8HASPIN
SCHEMBL30420636 0.82 ALDH1A1 (0.40) NR3C2ALDH1A1AURKACDK1AURKB
SCHEMBL29894910 0.82 ALDH1A1 (0.40) NR3C2ALDH1A1CCNCCDK8HASPIN
SCHEMBL22125728 0.82 L3MBTL1 (0.52) NR3C2ALDH1A1CCNCCDK8L3MBTL1
SCHEMBL30999737 0.82 ALDH1A1 (0.40) NR3C2ALDH1A1AURKACDK1AURKB
SCHEMBL30281252 0.81 ALDH1A1 (0.42) NR3C2ALDH1A1CCNCCDK8HASPIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630115-A1 THERAPEUTIC COMPOUNDS Sanofi (FR) 2025-10-15 — — EP claimed
EP-4486737-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO Pharma A/S (DK) 2025-01-08 — — EP claimed
WO-2024121427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2024-06-13 — — WO claimed
WO-2024115662-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2024-06-06 — — WO claimed
WO-2023166172-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2023-09-07 — — WO claimed
WO-2023111181-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2023-06-22 — — WO claimed
EP-3897623-A1 AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 Leo Pharma A/S (DK) 2021-10-27 — — EP claimed
WO-2020127685-A1 AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2020-06-25 — — WO claimed
US-20260083708-A1 IL-17 MODULATORS AND USES THEREOF NNOCARE PHARMA INC (US) 2026-03-26 — — US disclosed
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-11-20 — — US disclosed
EP-4630115-A1 THERAPEUTIC COMPOUNDS Sanofi (FR) 2025-10-15 — — EP disclosed
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-10 — — US disclosed
US-20250197378-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA AS (DK) 2025-06-19 — — US disclosed
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-27 — — US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 — — EP disclosed
EP-2350017-A1 AMIDE COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2011-08-03 — — EP disclosed
WO-2010032200-A1 AMIDE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2010-03-25 — — WO disclosed
CN-101675040-A 2-pyridinecarboxamide derivatives as sodium channel modulators PFIZER LTD 2010-03-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins ASGR1, FCGR2A, FCGR3B NR3C2 2798/4885ALDH1A1 3256/4885AURKA 3563/4885
US-20250197378-A1 SMALL MOLECULE MODULATORS OF IL-17 IL17A, IL2, IL23R NR3C2 601/4885ALDH1A1 429/4885AURKA 4164/4885
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF IL17A, IL15, IL23R NR3C2 717/4885ALDH1A1 536/4885AURKA 2445/4885
US-20250223280-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B NR3C2 2798/4885ALDH1A1 3256/4885AURKA 3563/4885
US-20260083708-A1 IL-17 MODULATORS AND USES THEREOF IL17A, IL2, IL23R NR3C2 13/4885ALDH1A1 1481/4885AURKA 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.